美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

PagerDuty, Inc.

15.16

-0.0700-0.46%

成交量：24.75萬

成交額：374.96萬

市值：13.97億

市盈率：-37.64

高：15.31

開：15.13

低：15.05

收：15.23

資料載入中...

總覽公司新聞公告

PagerDuty：2025年Q4財報實現營收1.214億美元，前值為1.111億美元

PagerDuty Inc 報告截至 1 月 31 日的季度業績 - 收益摘要

PagerDuty 2025 財年第四季度調整後每股收益 $0.22 高於預期 $0.16，銷售額 $121.40百萬高於預期 $119.77百萬

輝瑞(PFE)PD-L1靶向ADC新藥在華獲批臨牀

美國研究綜述-Beam Therapeutics、Lennar、Redfin

輝瑞(PFE.US)PD-L1靶向ADC新藥在華獲批臨牀擬治療晚期實體瘤

阿斯利康PD-L1在中國獲批第4項適應證 AI醫療概念股集體走強丨醫藥早參

每日经济新闻

阿斯利康PD-L1腫瘤藥在中國獲批第四項適應證

阿斯利康(AZN.US)胃癌圍手術期PD-L1聯合療法優於標準治療

【康方生物：依沃西頭對頭帕博利珠單抗Ⅲ期臨牀研究結果在《柳葉刀》發表】近日，康方生物自主研發的全球首創PD-1/VEGF雙特異性抗體新藥依沃西單藥對比帕博利珠單抗單藥一線治療PD-L1表達陽性的局部晚期或轉移性非小細胞肺癌的註冊性Ⅲ期臨牀研究(HARMONi-2/AK112-303）的研究數據，在國際頂級醫學期刊《柳葉刀》發表。

【基石藥業-B(02616.HK)在澳大利亞遞交CS5001(ROR1 ADC)聯合標準治療用於一線瀰漫大B細胞淋巴瘤的臨牀試驗申請】基石藥業-B(02616.HK)發佈公告，公司已在澳大利亞成功遞交CS5001(ROR1 ADC)聯合標準治療用於一線瀰漫大B細胞淋巴瘤(DLBCL)的Ib期臨牀試驗申請。此外 CS5001單藥及聯合PD-L1單抗治療晚期實體瘤的全球多中心臨牀試驗也在同步開展。

【百濟神州：百澤安在美國獲批用於晚期食管鱗狀細胞癌聯合化療的一線治療】3月4日，百濟神州宣佈，美國食品藥品監督管理局已批准百澤安®聯合含鉑化療用於腫瘤表達PD-L1的不可切除或轉移性食管鱗狀細胞癌成人患者一線治療。百澤安®已在美國獲批作為單藥用於治療既往接受過系統化療後不可切除或轉移性ESCC的成人患者，以及聯合化療用於胃和胃食管結合部癌成人患者的一線治療。

基石藥業PD-1/VEGF/CTLA-4三抗CS2009全球多中心I期臨牀試驗完成首例患者給藥

每日经济新闻

交銀國際：升百濟神州目標價至208.8港元維持買入評級

【基石藥業-B(02616.HK)：PD-1/VEGF/CTLA-4三特異性抗體CS2009全球多中心I期臨牀試驗順利完成首例患者給藥】基石藥業-B(02616.HK)發佈公告，公司自主研發的PD-1/VEGF/CTLA-4三特異性抗體CS2009的全球多中心I期臨牀試驗順利完成首例患者給藥，未發生輸液反應或其他不良事件。

基石藥業-B(02616)：PD-1/VEGF/CTLA-4三特異性抗體CS2009全球多中心I期臨牀試驗順利完成首例患者給藥

頭對頭帕博利珠單抗，信達生物IBI363（PD-1/IL-2α-bias雙特異性抗體融合蛋白）首個關鍵註冊臨牀研究完成首例受試者給藥，用於治療黑色素瘤

神州細胞抗PD-1單抗聯合療法獲批，百利天恆GNC-038 四抗注射液殺入自免領域，強生古塞奇尤單抗在華獲批克羅恩病適應症

医药经济报

【首個自研ADC澳洲臨牀入組康方生物IO 2+ADC戰略再進一步】近日，康方生物宣佈，公司自主研發的差異化靶向人表皮生長因子受體3（HER3）ADC新藥AK138D1，治療晚期惡性腫瘤的I期臨牀研究在澳洲完成首例受試者入組。AK138D1是康方生物首個進入臨牀階段的ADC藥物。ADC藥物是康方生物在全球範圍內重塑治療格局，構建腫瘤治療新標準，以創新療法造福全球患者的重要力量，也是康方生物推進“IO 2.0+ADC”戰略的重要抓手。目前康方生物自主研發的全球首創雙抗新藥卡度尼利（PD-1/CTLA-4雙抗）和依沃西（PD-1/VEGF雙抗）均已獲批上市。康方生物是全球唯一擁有2個腫瘤免疫治療雙抗的製藥公司，在IO+ADC聯合戰略中已經建立了在腫瘤免疫端的全球領先優勢。AK138D1等差異化ADC藥物的開發，為康方生物充分挖掘創新產品組合的臨牀價值，持續迭代腫瘤療法開拓了更廣闊的空間。

【券商聚焦】交銀國際維持康方生物(09926)買入評級指PD-1雙抗+ADC聯用潛力值得期待

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PD/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":15.16,"timestamp":1749746396758,"preClose":15.23,"halted":0,"volume":247518,"delay":0,"floatShares":82275854,"shares":92173975,"eps":-0.402741,"marketStatus":"交易中","change":-0.07,"latestTime":"06-12 12:40:39 EDT","open":15.13,"high":15.305,"low":15.05,"amount":3749556.867714,"amplitude":0.016743,"askPrice":15.19,"askSize":475,"bidPrice":15.17,"bidSize":125,"shortable":3,"etf":0,"ttmEps":-0.402741,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1749758400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":15.23,"preHourTrading":{"tag":"盘前","latestPrice":15.18,"preClose":15.23,"latestTime":"09:24 EDT","volume":6,"amount":91.180002,"timestamp":1749734693403},"postHourTrading":{"tag":"盘后","latestPrice":15.22,"preClose":15.22,"latestTime":"19:11 EDT","volume":45416,"amount":691232.04,"timestamp":1749683468876},"volumeRatio":0.282867,"impliedVol":0.4829,"impliedVolPercentile":0.456},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","floatShares":82275854,"roa":"-3.27%","roe":"-19.13%","lyrEps":-0.591956,"volumeRatio":0.282867,"shares":92173975,"dividePrice":0,"high":15.305,"amplitude":0.016743,"preClose":15.23,"low":15.05,"week52Low":13.9401,"pbRate":"9.59","psRate":"2.93","week52High":23.12,"institutionHeld":0,"latestPrice":15.16,"committee":-0.583333,"eps":-0.402741,"divideRate":0,"volume":247518,"delay":0,"ttmEps":-0.402741,"open":15.13,"prevYearClose":18.26,"prevWeekClose":16.34,"prevMonthClose":14.26,"prevQuarterClose":18.27,"fiveDayClose":15.38,"twentyDayClose":16.73,"sixtyDayClose":18.51},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PD\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2519894779","title":"PagerDuty：2025年Q4財報實現營收1.214億美元，前值為1.111億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2519894779","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519894779?lang=zh_tw&edition=fundamental","pubTime":"2025-03-14 08:10","pubTimestamp":1741911033,"startTime":"0","endTime":"0","summary":"PagerDuty(PD.US)：2025年Q4财报实现营收1.214亿美元，前值为1.111亿美元，预期值为1.195亿美元；每股收益为0.22美元，前值为0.17美元，预期值为0.16美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250314082838ab649ec4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250314082838ab649ec4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PD"],"gpt_icon":0},{"id":"2519086018","title":"PagerDuty Inc 報告截至 1 月 31 日的季度業績 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2519086018","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519086018?lang=zh_tw&edition=fundamental","pubTime":"2025-03-14 05:57","pubTimestamp":1741903022,"startTime":"0","endTime":"0","summary":"PagerDuty Inc 报告截至 1 月 31 日的季度业绩 - 收益摘要PagerDuty Inc PD.N公布的截至1月31日的季度调整后每股收益为22美分，高于去年同期的每股收益17美分。13位分析师对该季度的平均预期为每股收益16美分。PagerDuty Inc公布的本季度每股收益为亏损12美分。该公司当季亏损 1060 万美元。本季度，PagerDuty Inc 的股价下跌了 11.0%。华尔街对 PagerDuty Inc 的 12 个月目标价中位数为 21.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4S3PW1PJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","BK4023","LU1169589451.USD","PD"],"gpt_icon":0},{"id":"1146565096","title":"PagerDuty 2025 財年第四季度調整後每股收益 $0.22 高於預期 $0.16，銷售額 $121.40百萬 高於預期 $119.77百萬","url":"https://stock-news.laohu8.com/highlight/detail?id=1146565096","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146565096?lang=zh_tw&edition=fundamental","pubTime":"2025-03-14 04:10","pubTimestamp":1741896634,"startTime":"0","endTime":"0","summary":"PagerDuty  公布其季度收益为每股 $0.22，较分析师一致预期的 $0.16 高出 37.5%。相比去年同期的每股收益 $0.17，本次数据增长了 29.41%。季度销售额为 $121.40 百万，超出分析师预期的 $119.77 百万，增长率为 1.36%。以上内容来自Benzinga Earnings专栏，原文如下：PagerDuty  reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.16 by 37.5 percent. This is a 29.41 percent increase over earnings of $0.17 per share from the same period last year.  The company reported quarterly sales of $121.40 million which beat the analyst consensus estimate of $119.77 ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"PagerDuty 2025 财年第四季度调整后每股收益 $0.22 高于预期 $0.16，销售额 $121.40百万 高于预期 $119.77百万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD"],"gpt_icon":0},{"id":"2518797147","title":"輝瑞(PFE)PD-L1靶向ADC新藥在華獲批臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2518797147","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518797147?lang=zh_tw&edition=fundamental","pubTime":"2025-03-11 17:07","pubTimestamp":1741684053,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国国家药监局药品审评中心 3月10日公示，辉瑞与Seagen联合开发的1类新药PF-08046054获得临床试验默示许可，拟开展转移性或不可切除晚期实体瘤适应症研究。该药物是辉瑞研发管线中首款靶向PD-L1的抗体偶联药物，具有\"first-in-class\"潜力。PF-08046054采用独特的抗PD-L1抗体-药物偶联设计，由抗PD-L1单抗、可裂解连接子及微管抑制剂MMAE组成。相较于传统PD-1/PD-L1抑制剂，该药物通过结合ADC的双重作用机制，可能为PD-L1表达不足或耐药的实体瘤患者提供新治疗选择。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"286261","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","LU1894683264.USD","BK4568","BK4534","LU0321505439.SGD","BK4080","LU0289739699.SGD","LU0321505868.SGD","PD","SG9999002232.USD","LU0985481810.HKD","BK4023","SG9999001176.USD","BK4533","LU0225771236.USD","LU1169590202.USD","BK4007","LU0225284248.USD","LU0058720904.USD","ADC","SG9999002224.SGD","SGXZ57979304.SGD","BK4231","SG9999001176.SGD","SG9999003800.SGD","IE00B19Z3B42.SGD","LU1023059063.AUD","LU0456855351.SGD","LU0170899867.USD","IE00BBT3K403.USD","IE00BLSP4452.SGD","LU1883839398.USD","BK4588","BK4585","LU1066053197.SGD","LU0306807586.USD","IE000M9KFDE8.USD","BK4581","IE00BLSP4239.USD","LU1894683348.USD","BK4550","LU0122379950.USD","LU1066051498.USD","IE00B19Z3581.USD","PFE","LU0868494617.USD","LU1057294990.SGD","BK4592","LU1169589451.USD","SG9999013999.USD"],"gpt_icon":1},{"id":"2518761974","title":"美國研究綜述-Beam Therapeutics、Lennar、Redfin","url":"https://stock-news.laohu8.com/highlight/detail?id=2518761974","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518761974?lang=zh_tw&edition=fundamental","pubTime":"2025-03-11 15:08","pubTimestamp":1741676928,"startTime":"0","endTime":"0","summary":"美国研究综述-Beam Therapeutics、Lennar、Redfin路透3月11日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Beam Therapeutics、Lennar 和 Redfin。要闻  * Beam Therapeutics Inc BEAM.O：Jonestrading将其评级从 \"持有 \"上调至 \"买入\"。* Asana Inc ASAN.N：杰富瑞将目标价从19美元下调至15美元 * Asana Inc ASAN.N：摩根大通将目标价从15美元下调至13美元 * Beam Therapeutics Inc BEAM.O：Jonestrading将其评级从 \"持有 \"上调至 \"买入\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nL4S3PU0GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","PD","BK4213","CRBU","GIS","ASAN","TKO","IE00B7SZLL34.SGD","LU0985489474.SGD","LU1429558221.USD","TBRG","LU2023250843.SGD","IE0004445239.USD","LU0965509283.SGD","USAC","LU0820561909.HKD","LU2360106780.USD","NOW","LU0820561818.USD","BK4108","CDE","SFM","LU0345769631.USD","IE00BLSP4239.USD","LU1934455194.USD","PAY","LU0323591593.USD","RDFN","KGS","LU0738911758.USD","BK4516","LU2087625088.SGD","BK4596","LU0056508442.USD","LEN","LU2125909759.SGD","VG","BK4187","LU0965508806.USD","BK4227","LU0353189763.USD","BEAM","BK4556","LU0109391861.USD","LU0672654240.SGD","BK4581","LU0719512351.SGD","SARO","LU0861579265.USD"],"gpt_icon":1},{"id":"2518980763","title":"輝瑞(PFE.US)PD-L1靶向ADC新藥在華獲批臨牀 擬治療晚期實體瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2518980763","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518980763?lang=zh_tw&edition=fundamental","pubTime":"2025-03-11 14:10","pubTimestamp":1741673430,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月10日，中国国家药监局药品审评中心官网最新公示，辉瑞公司旗下Seagen申报的1类新药PF-08046054获得临床试验默示许可，拟开发治疗转移性或不可切除的晚期实体瘤。公开资料显示，这是辉瑞在研的一款潜在“first-in-class”PD-L1靶向抗体偶联药物。截图来源：CDE官网根据辉瑞公开资料介绍，PF-08046054是一款靶向PD-L1的ADC，由抗PD-L1抗体、连接子和微管破坏剂MMAE组成，可通过直接细胞毒性、旁观者杀伤、免疫原性细胞死亡来发挥抗肿瘤活性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4550","LU1894683348.USD","LU1894683264.USD","IE0002270589.USD","IE00BLSP4452.SGD","LU1883839398.USD","LU0225771236.USD","LU0122379950.USD","SG9999001176.USD","LU0868494617.USD","LU0985481810.HKD","LU1169589451.USD","BK4231","LU1023059063.AUD","LU0321505439.SGD","LU1169590202.USD","BK4534","BK4592","LU1066051498.USD","LU0306806265.USD","SG9999001176.SGD","SG9999011175.SGD","BK4585","SG9999002232.USD","SG9999013999.USD","PD","LU0234572021.USD","LU1066053197.SGD","BK4581","BK4588","BK4599","BK4023","LU0058720904.USD","SG9999003800.SGD","SGXZ57979304.SGD","BK4080","LU1057294990.SGD","ADC","BK4007","LU0306807586.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","PFE","BK4533","IE00B19Z3581.USD","IE00BBT3K403.USD","LU0225284248.USD","LU0321505868.SGD","LU0170899867.USD","SG9999002224.SGD"],"gpt_icon":1},{"id":"2518787053","title":"阿斯利康PD-L1在中國獲批第4項適應證 AI醫療概念股集體走強丨醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2518787053","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518787053?lang=zh_tw&edition=fundamental","pubTime":"2025-03-11 07:33","pubTimestamp":1741649613,"startTime":"0","endTime":"0","summary":"阿斯利康PD-L1在中国获批第4项适应证 AI医疗概念股集体走强丨医药早参","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503113341709854.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503113341709854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LU2236285917.USD","LU2417539215.USD","LU2456880835.USD","AZN","BK4568","LU2462157665.USD","BK1515","LU0320765992.SGD","09939","BK4585","LU0889565916.HKD","LU1169590202.USD","LU1169589451.USD","LU1829250122.USD","BK1574","BK4023","LU0109394709.USD","BK4007","BK4588","PD"],"gpt_icon":0},{"id":"2518248700","title":"阿斯利康PD-L1腫瘤藥在中國獲批第四項適應證","url":"https://stock-news.laohu8.com/highlight/detail?id=2518248700","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518248700?lang=zh_tw&edition=fundamental","pubTime":"2025-03-10 18:01","pubTimestamp":1741600887,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0320765992.SGD","BK4568","BK4588","LU0889565916.HKD","LU1169589451.USD","LU2417539215.USD","AZN","BK4585","BK4007","LU1169590202.USD","BK4023","ALK","LU1829250122.USD","LU0109394709.USD","BK4008","PD","LU2236285917.USD","LU2456880835.USD","LU2462157665.USD","BK4500"],"gpt_icon":0},{"id":"2517438513","title":"阿斯利康(AZN.US)胃癌圍手術期PD-L1聯合療法優於標準治療","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438513","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438513?lang=zh_tw&edition=fundamental","pubTime":"2025-03-07 21:20","pubTimestamp":1741353606,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月7日，阿斯利康宣布III期MATTERHORN研究结果显示，Imfinzi联合标准治疗FLOT化疗作为可切除的早期和局部晚期的胃癌和胃食管交界处癌患者围手术期治疗方案，主要终点无事件生存期具有统计学意义和临床意义的改善。MATTERHORN是首个证明免疫疗法联合治疗优于标准治疗的全球随机III期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0109394709.USD","LU2236285917.USD","LU2417539215.USD","BK4585","PD","AZN","LU1169589451.USD","BK4007","LU2462157665.USD","BK4023","BK4588","LU1829250122.USD","LU1169590202.USD","LU0889565916.HKD","LU0320765992.SGD","LU2456880835.USD","BK4568"],"gpt_icon":0},{"id":"2517122840","title":"【康方生物：依沃西頭對頭帕博利珠單抗Ⅲ期臨牀研究結果在《柳葉刀》發表】 近日，康方生物自主研發的全球首創PD-1/VEGF雙特異性抗體新藥依沃西單藥對比帕博利珠單抗單藥一線治療PD-L1表達陽性的局部晚期或轉移性非小細胞肺癌的註冊性Ⅲ期臨牀研究(HARMONi-2/AK112-303）的研究數據，在國際頂級醫學期刊《柳葉刀》發表。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517122840","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517122840?lang=zh_tw&edition=fundamental","pubTime":"2025-03-07 13:57","pubTimestamp":1741327045,"startTime":"0","endTime":"0","summary":"近日，康方生物自主研发的全球首创PD-1/VEGF双特异性抗体新药依沃西单药对比帕博利珠单抗单药一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌的注册性Ⅲ期临床研究(HARMONi-2/AK112-303）的研究数据，在国际顶级医学期刊《柳叶刀》发表。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/07135748586398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0417516571.SGD","BK1161","BK4023","LU0348784397.USD","LU1169590202.USD","LU1720050803.USD","IE00B543WZ88.USD","LU0348783233.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU1794554557.SGD","09926","BK1574","PD","LU1169589451.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2517497936","title":"【基石藥業-B(02616.HK)在澳大利亞遞交CS5001(ROR1 ADC)聯合標準治療用於一線瀰漫大B細胞淋巴瘤的臨牀試驗申請】基石藥業-B(02616.HK)發佈公告，公司已在澳大利亞成功遞交CS5001(ROR1 ADC)聯合標準治療用於一線瀰漫大B細胞淋巴瘤(DLBCL)的Ib期臨牀試驗申請。此外 CS5001單藥及聯合PD-L1單抗治療晚期實體瘤的全球多中心臨牀試驗也在同步開展。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517497936","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517497936?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 08:13","pubTimestamp":1741220034,"startTime":"0","endTime":"0","summary":"基石药业-B(02616.HK)发布公告，公司已在澳大利亚成功递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤(DLBCL)的Ib期临床试验申请。此外 CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06081348552983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","LU1169589451.USD","BK4231","LU1169590202.USD","BK4080","BK1576","02616","03347","BK1161","PD","ADC","BK1574","BK1583","BK4023"],"gpt_icon":0},{"id":"2517802379","title":"【百濟神州：百澤安在美國獲批用於晚期食管鱗狀細胞癌聯合化療的一線治療】3月4日，百濟神州宣佈，美國食品藥品監督管理局已批准百澤安®聯合含鉑化療用於腫瘤表達PD-L1的不可切除或轉移性食管鱗狀細胞癌成人患者一線治療。百澤安®已在美國獲批作為單藥用於治療既往接受過系統化療後不可切除或轉移性ESCC的成人患者，以及聯合化療用於胃和胃食管結合部癌成人患者的一線治療。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517802379","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517802379?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 07:10","pubTimestamp":1741129814,"startTime":"0","endTime":"0","summary":"3月4日，百济神州宣布，美国食品药品监督管理局已批准百泽安®联合含铂化疗用于肿瘤表达PD-L1的不可切除或转移性食管鳞状细胞癌成人患者一线治疗。百泽安®已在美国获批作为单药用于治疗既往接受过系统化疗后不可切除或转移性ESCC的成人患者，以及联合化疗用于胃和胃食管结合部癌成人患者的一线治疗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05071048524623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","LU0588546209.SGD","06160","LU1169589451.USD","PD","BK1583","LU2328871848.SGD","ONC","BK1500","LU0307460666.USD","LU1169590202.USD","BK4139","BK4023","LU1969619763.USD","688235","BK1161","BK1588"],"gpt_icon":0},{"id":"2516690737","title":"基石藥業PD-1/VEGF/CTLA-4三抗CS2009全球多中心I期臨牀試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2516690737","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516690737?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 10:43","pubTimestamp":1741056197,"startTime":"0","endTime":"0","summary":"每经AI快讯，基石药业今日宣布，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。该试验将深入评估CS2009在多种晚期实体瘤中的临床应用价值，包括非小细胞肺癌、肝癌、胃癌、子宫内膜癌、卵巢癌、肾细胞癌及宫颈癌等，进而推动肿瘤免疫疗法的创新与发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503043335813894.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043335813894.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","BK4023","LU1169590202.USD","PD","03347","BK1576","LU1169589451.USD","BK1583"],"gpt_icon":0},{"id":"2516697852","title":"交銀國際：升百濟神州目標價至208.8港元 維持買入評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2516697852","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516697852?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 10:25","pubTimestamp":1741055132,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["06160","159399","LU2328871848.SGD","BK4134","LU1169590202.USD","BK1161","BK1588","ONC","BK1583","LU0307460666.USD","BK4023","III","PD","BK0239","LU1169589451.USD","688235","BK4139","LU0588546209.SGD","BK1500","LU1969619763.USD"],"gpt_icon":0},{"id":"2516984776","title":"【基石藥業-B(02616.HK)：PD-1/VEGF/CTLA-4三特異性抗體CS2009全球多中心I期臨牀試驗順利完成首例患者給藥】基石藥業-B(02616.HK)發佈公告，公司自主研發的PD-1/VEGF/CTLA-4三特異性抗體CS2009的全球多中心I期臨牀試驗順利完成首例患者給藥，未發生輸液反應或其他不良事件。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516984776","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516984776?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 08:10","pubTimestamp":1741047048,"startTime":"0","endTime":"0","summary":"基石药业-B(02616.HK)发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04081048500557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","03347","BK1161","LU1169590202.USD","BK1583","BK1574","BK4023","02616","PD","LU1169589451.USD","BK1576"],"gpt_icon":0},{"id":"2516698610","title":"基石藥業-B(02616)：PD-1/VEGF/CTLA-4三特異性抗體CS2009全球多中心I期臨牀試驗順利完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2516698610","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516698610?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 08:06","pubTimestamp":1741046794,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。目前，CS2009率先在澳大利亚开展多中心I期临床试验，未来将陆续扩展至中国及美国。据悉，CS2009是一款靶向PD-1、VEGFA及CTLA-4的三特异性分子，作为靶向大瘤种的三特异性抗体，具备同类首创/同类最优潜力。临床前数据显示，CS2009具有明显优于潜在竞品的抗肿瘤活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4023","LU1169590202.USD","BK1141","BK1583","03347","02616","BK1574","PD","LU1169589451.USD","BK1576"],"gpt_icon":0},{"id":"2516452525","title":"頭對頭帕博利珠單抗，信達生物IBI363（PD-1/IL-2α-bias雙特異性抗體融合蛋白）首個關鍵註冊臨牀研究完成首例受試者給藥，用於治療黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2516452525","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516452525?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 08:00","pubTimestamp":1740960000,"startTime":"0","endTime":"0","summary":"目前，IBI363已开出首个关键注册临床研究，用于治疗未经免疫治疗的粘膜型和肢端型黑色素瘤。另外，IBI363已获美国FDA两项快速通道资格认定，分别用于治疗鳞状非小细胞肺癌和黑色素瘤。截至目前，信达生物患者援助项目已惠及20余万普通患者，药物捐赠总","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4631081_ZH31081_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1169590202.USD","LU1969619763.USD","LU1169589451.USD","LU2328871848.SGD","01801","BK1589","LU2488822045.USD","BK1583","BK4023","PD","IVBIY","BK4139","BK1161"],"gpt_icon":0},{"id":"2516580463","title":"神州細胞抗PD-1單抗聯合療法獲批，百利天恆GNC-038 四抗注射液殺入自免領域，強生古塞奇尤單抗在華獲批克羅恩病適應症","url":"https://stock-news.laohu8.com/highlight/detail?id=2516580463","media":"医药经济报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516580463?lang=zh_tw&edition=fundamental","pubTime":"2025-03-01 11:48","pubTimestamp":1740800927,"startTime":"0","endTime":"0","summary":"神州细胞抗PD-1单抗联合疗法获批，一线治疗肝癌2月28日，中国国家药监局官网公示，神州细胞控股子公司神州细胞工程递交的菲诺利单抗注射液与贝伐珠单抗注射液联合疗法的上市许可申请已获得批准。菲诺利单抗为神州细胞自主研发的重组人源化抗PD-1 IgG4型单克隆抗体注射液，首个适应症头颈部鳞状细胞癌已经于2025年2月获NMPA批准上市。这一消息标志着古塞奇尤单抗在克罗恩病适应症上的全球首个批准，为国内克罗恩病患者带来了新的希望。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301115219abe18cd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301115219abe18cd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1061106388.HKD","LU1732800096.USD","JNJ","BK4592","LU1732799900.SGD","LU2430703251.USD","LU1023059063.AUD","688520","IE00BDGV0183.EUR","LU1032466523.USD","LU1674673691.USD","LU2468319806.SGD","LU2129689514.USD","LU0058720904.USD","LU0289739699.SGD","LU2129689605.HKD","LU2505996509.AUD","LU2089984988.USD","IE00BVYPNW00.USD","LU1032955483.USD","IE000M9KFDE8.USD","BK4023","LU1929549753.HKD","IE00BJT1NW94.SGD","LU1267930813.SGD","LU0795875169.SGD","IE00B2B36J28.USD","BK4504","IE00B42XCP33.USD","LU1059921491.USD","PD","LU1244550221.USD","SG9999002232.USD","IE00B19Z3581.USD","LU2592432038.USD","LU1066051225.USD","IE00BGHQF631.EUR","LU1162221912.USD","IE0009355771.USD","IE0034235303.USD","BK4550","LU2112291526.USD","LU1221951046.USD","BK4559","LU1914381329.SGD","BK4007","688506","SG9999001440.SGD","IE0002141913.USD","LU0234570918.USD","BK4533","LU2505996681.GBP"],"gpt_icon":0},{"id":"2514818522","title":"【首個自研ADC澳洲臨牀入組 康方生物IO 2+ADC戰略再進一步】近日，康方生物宣佈，公司自主研發的差異化靶向人表皮生長因子受體3（HER3）ADC新藥AK138D1，治療晚期惡性腫瘤的I期臨牀研究在澳洲完成首例受試者入組。AK138D1是康方生物首個進入臨牀階段的ADC藥物。ADC藥物是康方生物在全球範圍內重塑治療格局，構建腫瘤治療新標準，以創新療法造福全球患者的重要力量，也是康方生物推進“IO 2.0+ADC”戰略的重要抓手。目前康方生物自主研發的全球首創雙抗新藥卡度尼利（PD-1/CTLA-4雙抗）和依沃西（PD-1/VEGF雙抗）均已獲批上市。康方生物是全球唯一擁有2個腫瘤免疫治療雙抗的製藥公司，在IO+ADC聯合戰略中已經建立了在腫瘤免疫端的全球領先優勢。AK138D1等差異化ADC藥物的開發，為康方生物充分挖掘創新產品組合的臨牀價值，持續迭代腫瘤療法開拓了更廣闊的空間。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514818522","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514818522?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 08:40","pubTimestamp":1740616816,"startTime":"0","endTime":"0","summary":"AK138D1是康方生物首个进入临床阶段的ADC药物。ADC药物是康方生物在全球范围内重塑治疗格局，构建肿瘤治疗新标准，以创新疗法造福全球患者的重要力量，也是康方生物推进“IO 2.0+ADC”战略的重要抓手。康方生物是全球唯一拥有2个肿瘤免疫治疗双抗的制药公司，在IO+ADC联合战略中已经建立了在肿瘤免疫端的全球领先优势。AK138D1等差异化ADC药物的开发，为康方生物充分挖掘创新产品组合的临床价值，持续迭代肿瘤疗法开拓了更广阔的空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27084048415964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0348784397.USD","LU0329678337.USD","LU1794554557.SGD","BK1583","BK1191","LU1169589451.USD","BK4231","IE00B543WZ88.USD","BK1574","LU1169590202.USD","09926","LU0737861772.HKD","BK1161","PD","LU0417516571.SGD","01477","BK4023","IE00B5MMRT66.SGD","BK1209","BK4080","LU0348783233.USD","LU2488822045.USD","ADC","IE00BPRC5H50.USD","LU1720050803.USD","LU0329678170.USD","06078"],"gpt_icon":0},{"id":"2514021200","title":"【券商聚焦】交銀國際維持康方生物(09926)買入評級 指PD-1雙抗+ADC聯用潛力值得期待","url":"https://stock-news.laohu8.com/highlight/detail?id=2514021200","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514021200?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 08:59","pubTimestamp":1740531544,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，康方生物 依沃西将与辉瑞公司多个ADCs药物开展联合疗法临床试验：2月24日， Summit Therapeutics 宣布与辉瑞达成临床试验合作，共同推进 PD1/VEGF 双抗依沃西与辉瑞多款vedotin ADC 在多种实体瘤中的联合治疗应用。辉瑞将全面负责临床试验的开展及相关费用，Summit将提供依沃西并参与海外研究。初步临床结果显示，PD-1靶向药物能与vedotin ADC形成协同效应。该行维持买入评级和87港元目标价，并继续将公司选为行业重点推荐标的之一。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1953886","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","ADC","09926"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":6,"totalSize":159,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-29","symbol":"PD","fiscalQuarterEnding":"2025/04","expectedEps":-0.06,"name":null,"time":"盤後","type":"earning","dateTimestamp":1748491200000,"reportTimeType":"post","actualEps":0},{"market":"US","date":"2025-03-13","symbol":"PD","fiscalQuarterEnding":"2025/01","expectedEps":-0.12,"name":null,"time":"盤後","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2024-11-26","symbol":"PD","fiscalQuarterEnding":"2024/10","expectedEps":-0.11,"name":null,"time":"盤後","type":"earning","dateTimestamp":1732597200000,"reportTimeType":"post","actualEps":-0.03},{"market":"US","date":"2024-09-03","symbol":"PD","fiscalQuarterEnding":"2024/07","expectedEps":-0.12,"name":null,"time":"盤後","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2024-05-30","symbol":"PD","fiscalQuarterEnding":"2024/04","expectedEps":-0.11,"name":null,"time":"盤後","type":"earning","dateTimestamp":1717041600000,"reportTimeType":"post","actualEps":-0.11}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.0769,"buy":0.3077,"hold":0.4615,"sell":0.1538,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.4615,"analysts":13,"updateTime":1738296000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PD","date":"2025-06-11","current":-39.541314,"percent":0.259106,"low":-81.051795,"twenty":-42.85482,"median":-25.054079,"eighty":-20.118618,"high":-13.794086,"avg":-30.406761,"sd":13.393442,"marketCap":1459114024},"quantilePoints":[{"date":"2020-06-12","current":-39.198908,"twenty":-75.187331,"median":-42.329073,"eighty":-36.817602,"marketCap":1949518515},{"date":"2020-06-19","current":-48.393323,"twenty":-74.002242,"median":-42.496137,"eighty":-36.834452,"marketCap":2406793548},{"date":"2020-06-26","current":-46.067026,"twenty":-73.969323,"median":-42.888728,"eighty":-36.850607,"marketCap":2291097455},{"date":"2020-07-02","current":-47.49129,"twenty":-73.92982,"median":-42.964871,"eighty":-36.863809,"marketCap":2361931798},{"date":"2020-07-10","current":-44.658587,"twenty":-72.98504,"median":-43.055636,"eighty":-36.906716,"marketCap":2221050161},{"date":"2020-07-17","current":-40.765599,"twenty":-72.685476,"median":-42.964871,"eighty":-36.931288,"marketCap":2027436292},{"date":"2020-07-24","current":-42.807044,"twenty":-72.640646,"median":-42.989625,"eighty":-37.118318,"marketCap":2128965516},{"date":"2020-07-31","current":-48.235072,"twenty":-72.530247,"median":-43.175427,"eighty":-37.208604,"marketCap":2398923066},{"date":"2020-08-07","current":-47.238087,"twenty":-72.318638,"median":-43.360924,"eighty":-37.407321,"marketCap":2349339026},{"date":"2020-08-14","current":-46.177802,"twenty":-72.098738,"median":-43.468321,"eighty":-37.467623,"marketCap":2296606793},{"date":"2020-08-21","current":-45.95625,"twenty":-71.69039,"median":-43.550826,"eighty":-37.518859,"marketCap":2285588118},{"date":"2020-08-28","current":-48.583225,"twenty":-71.41486,"median":-43.699242,"eighty":-37.630539,"marketCap":2416238127},{"date":"2020-09-04","current":-38.528058,"twenty":-71.368789,"median":-43.748751,"eighty":-37.658486,"marketCap":1997756875},{"date":"2020-09-11","current":-36.766338,"twenty":-71.24954,"median":-43.637964,"eighty":-37.464273,"marketCap":1906408152},{"date":"2020-09-18","current":-38.03784,"twenty":-70.931543,"median":-43.525964,"eighty":-37.424178,"marketCap":1972338100},{"date":"2020-09-25","current":-40.596165,"twenty":-70.750862,"median":-43.369188,"eighty":-37.464273,"marketCap":2104992334},{"date":"2020-10-02","current":-42.378825,"twenty":-69.760733,"median":-43.304333,"eighty":-37.506887,"marketCap":2197426830},{"date":"2020-10-09","current":-45.308378,"twenty":-68.893466,"median":-43.360924,"eighty":-37.540906,"marketCap":2349330024},{"date":"2020-10-16","current":-46.719472,"twenty":-68.681421,"median":-43.459295,"eighty":-37.566006,"marketCap":2422498055},{"date":"2020-10-23","current":-44.664183,"twenty":-67.026675,"median":-43.550718,"eighty":-37.624584,"marketCap":2315927228},{"date":"2020-10-30","current":-41.565912,"twenty":-65.321463,"median":-43.550772,"eighty":-37.657731,"marketCap":2155275682},{"date":"2020-11-06","current":-46.121291,"twenty":-64.742086,"median":-43.550826,"eighty":-37.676934,"marketCap":2391481172},{"date":"2020-11-13","current":-46.35136,"twenty":-63.787431,"median":-43.643849,"eighty":-37.728931,"marketCap":2403410742},{"date":"2020-11-20","current":-47.79313,"twenty":-62.855819,"median":-43.781756,"eighty":-37.757248,"marketCap":2478169382},{"date":"2020-11-27","current":-52.440537,"twenty":-62.329113,"median":-43.973974,"eighty":-37.811067,"marketCap":2719146700},{"date":"2020-12-04","current":-58.503982,"twenty":-61.897872,"median":-44.116471,"eighty":-37.910083,"marketCap":3346135266},{"date":"2020-12-11","current":-61.956348,"twenty":-61.897872,"median":-44.23472,"eighty":-37.979009,"marketCap":3543593297},{"date":"2020-12-18","current":-64.76408,"twenty":-63.261641,"median":-44.342085,"eighty":-38.134161,"marketCap":3704181571},{"date":"2020-12-24","current":-65.981719,"twenty":-64.468982,"median":-44.366057,"eighty":-38.286785,"marketCap":3773824445},{"date":"2020-12-31","current":-59.735947,"twenty":-64.377301,"median":-44.622066,"eighty":-38.319351,"marketCap":3416597468},{"date":"2021-01-08","current":-63.775644,"twenty":-64.248374,"median":-44.664183,"eighty":-38.342002,"marketCap":3647647944},{"date":"2021-01-15","current":-65.265461,"twenty":-64.491902,"median":-44.85652,"eighty":-38.342002,"marketCap":3732858049},{"date":"2021-01-22","current":-70.007091,"twenty":-64.924465,"median":-44.940871,"eighty":-38.368803,"marketCap":4004055593},{"date":"2021-01-29","current":-69.806539,"twenty":-66.010369,"median":-45.124322,"eighty":-38.447577,"marketCap":3992585002},{"date":"2021-02-05","current":-78.774094,"twenty":-67.606194,"median":-45.279297,"eighty":-38.515566,"marketCap":4505484287},{"date":"2021-02-12","current":-81.051795,"twenty":-68.875403,"median":-45.308378,"eighty":-38.533013,"marketCap":4635757427},{"date":"2021-02-19","current":-74.533844,"twenty":-69.256452,"median":-45.492434,"eighty":-38.599807,"marketCap":4262963219},{"date":"2021-02-26","current":-64.090797,"twenty":-69.256452,"median":-45.616009,"eighty":-38.656949,"marketCap":3665673158},{"date":"2021-03-05","current":-53.862628,"twenty":-69.159583,"median":-45.671397,"eighty":-38.66724,"marketCap":3080673016},{"date":"2021-03-12","current":-60.509506,"twenty":-69.072496,"median":-45.726784,"eighty":-38.673459,"marketCap":3460841176},{"date":"2021-03-19","current":-49.639711,"twenty":-68.918379,"median":-45.797998,"eighty":-38.687063,"marketCap":3420324980},{"date":"2021-03-26","current":-46.372989,"twenty":-68.782324,"median":-45.852876,"eighty":-38.706425,"marketCap":3195238028},{"date":"2021-04-01","current":-49.627656,"twenty":-68.703922,"median":-45.852876,"eighty":-38.74149,"marketCap":3419494401},{"date":"2021-04-09","current":-50.688437,"twenty":-68.634603,"median":-45.95625,"eighty":-38.792193,"marketCap":3492585367},{"date":"2021-04-16","current":-50.965686,"twenty":-68.620415,"median":-46.098464,"eighty":-38.810779,"marketCap":3511688688},{"date":"2021-04-23","current":-50.965686,"twenty":-68.551655,"median":-46.177802,"eighty":-38.849388,"marketCap":3511688688},{"date":"2021-04-30","current":-51.182664,"twenty":-68.073194,"median":-46.296231,"eighty":-38.932876,"marketCap":3526639113},{"date":"2021-05-07","current":-45.52431,"twenty":-67.425697,"median":-46.35136,"eighty":-39.005886,"marketCap":3136761501},{"date":"2021-05-14","current":-42.286432,"twenty":-67.150653,"median":-46.187891,"eighty":-39.046881,"marketCap":2913662055},{"date":"2021-05-21","current":-44.081211,"twenty":-66.824039,"median":-46.121291,"eighty":-39.054259,"marketCap":3037327665},{"date":"2021-05-28","current":-49.295769,"twenty":-66.574781,"median":-46.172553,"eighty":-39.081958,"marketCap":3396626399},{"date":"2021-06-04","current":-36.968776,"twenty":-66.216652,"median":-46.172553,"eighty":-39.072116,"marketCap":2957576028},{"date":"2021-06-11","current":-42.279901,"twenty":-66.096321,"median":-46.075636,"eighty":-39.072116,"marketCap":3382476656},{"date":"2021-06-18","current":-45.709132,"twenty":-65.976077,"median":-45.923735,"eighty":-39.125091,"marketCap":3656821944},{"date":"2021-06-25","current":-47.162372,"twenty":-65.815901,"median":-46.067026,"eighty":-39.183405,"marketCap":3773084124},{"date":"2021-07-02","current":-44.130431,"twenty":-65.216755,"median":-46.011638,"eighty":-39.205083,"marketCap":3530522741},{"date":"2021-07-09","current":-45.834591,"twenty":-65.021933,"median":-45.883552,"eighty":-39.229781,"marketCap":3666858967},{"date":"2021-07-16","current":-40.199362,"twenty":-64.900098,"median":-45.829869,"eighty":-39.313533,"marketCap":3216029363},{"date":"2021-07-23","current":-43.325398,"twenty":-64.76408,"median":-45.766347,"eighty":-39.330284,"marketCap":3466118512},{"date":"2021-07-30","current":-42.436726,"twenty":-64.636745,"median":-45.712576,"eighty":-39.369202,"marketCap":3395022935},{"date":"2021-08-06","current":-44.33953,"twenty":-64.491902,"median":-45.685037,"eighty":-39.631794,"marketCap":3547251112},{"date":"2021-08-13","current":-42.269446,"twenty":-64.377301,"median":-45.655572,"eighty":-39.648544,"marketCap":3381640238},{"date":"2021-08-20","current":-40.387552,"twenty":-64.32,"median":-45.516041,"eighty":-39.732297,"marketCap":3231084897},{"date":"2021-08-27","current":-43.743597,"twenty":-64.248374,"median":-45.492434,"eighty":-39.784241,"marketCap":3499575255},{"date":"2021-09-03","current":-42.390054,"twenty":-64.090797,"median":-45.440934,"eighty":-39.784241,"marketCap":4025995391},{"date":"2021-09-10","current":-39.410762,"twenty":-63.838675,"median":-45.357157,"eighty":-39.773852,"marketCap":3743037083},{"date":"2021-09-17","current":-42.488469,"twenty":-63.43184,"median":-45.291593,"eighty":-39.773852,"marketCap":4035342362},{"date":"2021-09-24","current":-41.531159,"twenty":-63.322968,"median":-45.131991,"eighty":-39.806871,"marketCap":3944421825},{"date":"2021-10-01","current":-37.845067,"twenty":-63.294318,"median":-44.969953,"eighty":-39.673042,"marketCap":3594335269},{"date":"2021-10-08","current":-35.304169,"twenty":-63.234694,"median":-44.895964,"eighty":-39.361418,"marketCap":3353013468},{"date":"2021-10-15","current":-36.968279,"twenty":-62.977151,"median":-44.757709,"eighty":-39.195032,"marketCap":3511062253},{"date":"2021-10-22","current":-37.567716,"twenty":-62.673,"median":-44.689179,"eighty":-39.048237,"marketCap":3567993805},{"date":"2021-10-29","current":-37.352992,"twenty":-62.144822,"median":-44.662724,"eighty":-38.884343,"marketCap":3547600413},{"date":"2021-11-05","current":-38.927633,"twenty":-61.970673,"median":-44.622066,"eighty":-38.780249,"marketCap":3697151952},{"date":"2021-11-12","current":-37.684024,"twenty":-61.914834,"median":-44.517265,"eighty":-38.690435,"marketCap":3579040225},{"date":"2021-11-19","current":-34.892615,"twenty":-61.891288,"median":-44.350719,"eighty":-38.663132,"marketCap":3313926135},{"date":"2021-11-26","current":-33.094304,"twenty":-61.87812,"median":-44.340807,"eighty":-38.647574,"marketCap":3143131480},{"date":"2021-12-03","current":-27.717262,"twenty":-61.851785,"median":-44.310434,"eighty":-38.490518,"marketCap":2632446965},{"date":"2021-12-10","current":-29.437491,"twenty":-61.634212,"median":-44.193031,"eighty":-38.342002,"marketCap":2964590848},{"date":"2021-12-17","current":-29.446029,"twenty":-61.446371,"median":-44.130431,"eighty":-38.122419,"marketCap":2965450648},{"date":"2021-12-23","current":-30.863263,"twenty":-61.141525,"median":-44.120926,"eighty":-37.910083,"marketCap":3108177469},{"date":"2021-12-31","current":-29.668005,"twenty":-60.679678,"median":-44.096614,"eighty":-37.767931,"marketCap":2987805451},{"date":"2022-01-07","current":-27.243339,"twenty":-60.561077,"median":-44.020576,"eighty":-37.685906,"marketCap":2743622214},{"date":"2022-01-14","current":-26.466422,"twenty":-60.402519,"median":-43.931787,"eighty":-37.609143,"marketCap":2665380403},{"date":"2022-01-21","current":-25.715117,"twenty":-60.229637,"median":-43.82863,"eighty":-37.535067,"marketCap":2589717991},{"date":"2022-01-28","current":-27.448241,"twenty":-60.179262,"median":-43.748751,"eighty":-37.457573,"marketCap":2764257417},{"date":"2022-02-04","current":-27.106738,"twenty":-60.125395,"median":-43.643849,"eighty":-37.310047,"marketCap":2729865412},{"date":"2022-02-11","current":-28.728874,"twenty":-59.884929,"median":-43.550718,"eighty":-37.143446,"marketCap":2893227437},{"date":"2022-02-18","current":-27.106738,"twenty":-59.724487,"median":-43.492185,"eighty":-36.968378,"marketCap":2729865412},{"date":"2022-02-25","current":-28.071482,"twenty":-59.678646,"median":-43.437917,"eighty":-36.905651,"marketCap":2827022827},{"date":"2022-03-04","current":-25.322389,"twenty":-59.583656,"median":-43.360924,"eighty":-36.834452,"marketCap":2550167185},{"date":"2022-03-11","current":-22.70136,"twenty":-59.306192,"median":-43.319423,"eighty":-36.766338,"marketCap":2286208545},{"date":"2022-03-18","current":-28.291592,"twenty":-59.172166,"median":-43.295217,"eighty":-36.444632,"marketCap":3040073042},{"date":"2022-03-25","current":-28.785804,"twenty":-59.048339,"median":-43.241759,"eighty":-36.064649,"marketCap":3093178556},{"date":"2022-04-01","current":-27.724464,"twenty":-59.048339,"median":-43.1764,"eighty":-35.678665,"marketCap":2979132288},{"date":"2022-04-08","current":-25.415442,"twenty":-58.958192,"median":-43.086807,"eighty":-35.293402,"marketCap":2731016361},{"date":"2022-04-14","current":-26.428171,"twenty":-58.866018,"median":-43.039133,"eighty":-34.945236,"marketCap":2839839136},{"date":"2022-04-22","current":-23.843687,"twenty":-58.778063,"median":-42.940117,"eighty":-34.48789,"marketCap":2562123414},{"date":"2022-04-29","current":-23.14693,"twenty":-58.704534,"median":-42.888728,"eighty":-33.407653,"marketCap":2487253345},{"date":"2022-05-06","current":-21.039181,"twenty":-58.614907,"median":-42.82356,"eighty":-33.196501,"marketCap":2260765197},{"date":"2022-05-13","current":-21.537198,"twenty":-58.533862,"median":-42.744231,"eighty":-33.138326,"marketCap":2314279623},{"date":"2022-05-20","current":-19.528801,"twenty":-58.506847,"median":-42.67719,"eighty":-32.784627,"marketCap":2098467346},{"date":"2022-05-27","current":-21.055509,"twenty":-58.47232,"median":-42.506172,"eighty":-32.56425,"marketCap":2262519768},{"date":"2022-06-03","current":-19.41561,"twenty":-58.365647,"median":-42.492303,"eighty":-32.253988,"marketCap":2285547362},{"date":"2022-06-10","current":-18.661968,"twenty":-58.119439,"median":-42.449993,"eighty":-31.627913,"marketCap":2196830881},{"date":"2022-06-17","current":-17.871017,"twenty":-57.794408,"median":-42.412967,"eighty":-30.853018,"marketCap":2103722495},{"date":"2022-06-24","current":-21.251213,"twenty":-57.545961,"median":-42.37641,"eighty":-30.527663,"marketCap":2501629088},{"date":"2022-07-01","current":-18.975364,"twenty":-57.27835,"median":-42.328632,"eighty":-30.205871,"marketCap":2233722883},{"date":"2022-07-08","current":-20.758734,"twenty":-57.119373,"median":-42.300639,"eighty":-29.937792,"marketCap":2443655942},{"date":"2022-07-15","current":-19.512613,"twenty":-57.022546,"median":-42.274674,"eighty":-29.686169,"marketCap":2296966315},{"date":"2022-07-22","current":-19.751391,"twenty":-56.538634,"median":-42.258991,"eighty":-29.576542,"marketCap":2325074507},{"date":"2022-07-29","current":-19.348454,"twenty":-55.37095,"median":-42.1379,"eighty":-29.489533,"marketCap":2277641933},{"date":"2022-08-05","current":-21.340755,"twenty":-54.581356,"median":-41.999461,"eighty":-29.249821,"marketCap":2512169660},{"date":"2022-08-12","current":-21.370602,"twenty":-54.282209,"median":-41.907002,"eighty":-28.899625,"marketCap":2515683184},{"date":"2022-08-19","current":-19.214141,"twenty":-54.164004,"median":-41.742363,"eighty":-28.761236,"marketCap":2261831075},{"date":"2022-08-26","current":-19.318607,"twenty":-54.013801,"median":-41.687142,"eighty":-28.490216,"marketCap":2274128409},{"date":"2022-09-02","current":-16.562766,"twenty":-53.825684,"median":-41.612639,"eighty":-28.401837,"marketCap":2096100841},{"date":"2022-09-09","current":-17.753369,"twenty":-53.67791,"median":-41.5952,"eighty":-28.368118,"marketCap":2246777593},{"date":"2022-09-16","current":-16.597991,"twenty":-53.584381,"median":-41.569297,"eighty":-28.257217,"marketCap":2100558733},{"date":"2022-09-23","current":-15.858267,"twenty":-53.533149,"median":-41.530643,"eighty":-28.105632,"marketCap":2006943000},{"date":"2022-09-30","current":-16.252786,"twenty":-53.345477,"median":-41.466004,"eighty":-27.873415,"marketCap":2056871391},{"date":"2022-10-07","current":-16.182337,"twenty":-53.110426,"median":-41.390601,"eighty":-27.717262,"marketCap":2047955607},{"date":"2022-10-14","current":-14.646529,"twenty":-52.79331,"median":-41.34773,"eighty":-27.636067,"marketCap":1853591514},{"date":"2022-10-21","current":-16.485271,"twenty":-52.578578,"median":-41.307589,"eighty":-27.328715,"marketCap":2086293479},{"date":"2022-10-28","current":-17.922449,"twenty":-52.484531,"median":-41.281723,"eighty":-27.012825,"marketCap":2268175475},{"date":"2022-11-04","current":-14.604259,"twenty":-52.445692,"median":-41.223096,"eighty":-26.683037,"marketCap":1848242043},{"date":"2022-11-11","current":-17.35885,"twenty":-52.440537,"median":-41.165581,"eighty":-26.46868,"marketCap":2196849202},{"date":"2022-11-18","current":-15.442613,"twenty":-51.97825,"median":-41.046215,"eighty":-26.415612,"marketCap":1954339874},{"date":"2022-11-25","current":-15.379208,"twenty":-51.971496,"median":-40.952393,"eighty":-26.24103,"marketCap":1946315669},{"date":"2022-12-02","current":-16.042428,"twenty":-51.941247,"median":-40.886211,"eighty":-26.002015,"marketCap":2129728606},{"date":"2022-12-09","current":-16.110204,"twenty":-51.872986,"median":-40.837833,"eighty":-25.713912,"marketCap":2138726192},{"date":"2022-12-16","current":-18.028246,"twenty":-51.7604,"median":-40.772608,"eighty":-25.598799,"marketCap":2393357876},{"date":"2022-12-23","current":-17.994359,"twenty":-51.70784,"median":-40.745253,"eighty":-25.338499,"marketCap":2388859083},{"date":"2022-12-30","current":-18.001136,"twenty":-51.570726,"median":-40.701201,"eighty":-25.184081,"marketCap":2389758841},{"date":"2023-01-06","current":-16.049206,"twenty":-51.363479,"median":-40.623172,"eighty":-24.85486,"marketCap":2130628364},{"date":"2023-01-13","current":-18.78733,"twenty":-51.102161,"median":-40.574619,"eighty":-24.231092,"marketCap":2494130839},{"date":"2023-01-20","current":-18.882216,"twenty":-50.978262,"median":-40.523325,"eighty":-23.99114,"marketCap":2506727459},{"date":"2023-01-27","current":-19.925957,"twenty":-50.965686,"median":-40.469321,"eighty":-23.312385,"marketCap":2645290284},{"date":"2023-02-03","current":-21.220466,"twenty":-50.951221,"median":-40.311267,"eighty":-22.57339,"marketCap":2817144176},{"date":"2023-02-10","current":-19.627745,"twenty":-50.890949,"median":-40.250171,"eighty":-21.596594,"marketCap":2605700905},{"date":"2023-02-17","current":-20.664708,"twenty":-50.876484,"median":-40.190227,"eighty":-21.430411,"marketCap":2743363971},{"date":"2023-02-24","current":-19.485417,"twenty":-50.857197,"median":-40.120759,"eighty":-21.251213,"marketCap":2586805975},{"date":"2023-03-03","current":-20.834146,"twenty":-50.688437,"median":-40.045986,"eighty":-21.055509,"marketCap":2765857936},{"date":"2023-03-10","current":-18.204462,"twenty":-50.646894,"median":-39.953806,"eighty":-20.967665,"marketCap":2416751599},{"date":"2023-03-17","current":-22.814647,"twenty":-50.628165,"median":-39.81605,"eighty":-20.881589,"marketCap":2929925462},{"date":"2023-03-24","current":-22.508745,"twenty":-50.547877,"median":-39.758269,"eighty":-20.937818,"marketCap":2890640524},{"date":"2023-03-31","current":-24.884826,"twenty":-50.538628,"median":-39.648544,"eighty":-20.967665,"marketCap":3195783993},{"date":"2023-04-06","current":-22.608341,"twenty":-50.398102,"median":-39.410762,"eighty":-20.985573,"marketCap":2903430969},{"date":"2023-04-14","current":-23.753697,"twenty":-50.260054,"median":-39.321908,"eighty":-21.029355,"marketCap":3050521084},{"date":"2023-04-21","current":-24.273021,"twenty":-50.211876,"median":-39.198908,"eighty":-21.041663,"marketCap":3117214118},{"date":"2023-04-28","current":-22.053448,"twenty":-50.10983,"median":-39.086878,"eighty":-21.052864,"marketCap":2832169920},{"date":"2023-05-05","current":-20.085339,"twenty":-50.030853,"median":-39.045525,"eighty":-21.029355,"marketCap":2579419472},{"date":"2023-05-12","current":-21.254175,"twenty":-50.011348,"median":-38.97946,"eighty":-20.981096,"marketCap":2729524925},{"date":"2023-05-19","current":-21.074906,"twenty":-49.936988,"median":-38.858126,"eighty":-20.935287,"marketCap":2706502616},{"date":"2023-05-26","current":-18.98821,"twenty":-49.739821,"median":-38.781427,"eighty":-20.865452,"marketCap":2438522942},{"date":"2023-06-02","current":-23.7011,"twenty":-49.634889,"median":-38.748697,"eighty":-20.83367,"marketCap":2555476271},{"date":"2023-06-09","current":-19.16437,"twenty":-49.587066,"median":-38.685442,"eighty":-20.780404,"marketCap":2066321490},{"date":"2023-06-16","current":-19.591955,"twenty":-49.518553,"median":-38.668128,"eighty":-20.758997,"marketCap":2112424156},{"date":"2023-06-23","current":-18.642716,"twenty":-49.490829,"median":-38.652026,"eighty":-20.740419,"marketCap":2010076237},{"date":"2023-06-30","current":-18.830853,"twenty":-49.425691,"median":-38.650282,"eighty":-20.728887,"marketCap":2030361410},{"date":"2023-07-07","current":-18.753888,"twenty":-49.321753,"median":-38.534252,"eighty":-20.640309,"marketCap":2022062930},{"date":"2023-07-14","current":-21.12271,"twenty":-49.135663,"median":-38.486364,"eighty":-20.586625,"marketCap":2277471700},{"date":"2023-07-21","current":-20.626711,"twenty":-49.077653,"median":-38.375503,"eighty":-20.595005,"marketCap":2223992607},{"date":"2023-07-28","current":-21.105606,"twenty":-49.061015,"median":-38.330676,"eighty":-20.595005,"marketCap":2275627593},{"date":"2023-08-04","current":-20.883262,"twenty":-49.007339,"median":-38.158206,"eighty":-20.613914,"marketCap":2251654207},{"date":"2023-08-11","current":-20.549746,"twenty":-48.954208,"median":-37.988814,"eighty":-20.586625,"marketCap":2215694127},{"date":"2023-08-18","current":-20.01954,"twenty":-48.941266,"median":-37.845067,"eighty":-20.541194,"marketCap":2158526822},{"date":"2023-08-25","current":-20.66947,"twenty":-48.894876,"median":-37.770349,"eighty":-20.506987,"marketCap":2228602874},{"date":"2023-09-01","current":-25.511357,"twenty":-48.832826,"median":-37.755599,"eighty":-20.541194,"marketCap":2375209352},{"date":"2023-09-07","current":-24.043412,"twenty":-48.807682,"median":-37.686377,"eighty":-20.560008,"marketCap":2238537799},{"date":"2023-09-14","current":-23.412009,"twenty":-48.750972,"median":-37.671633,"eighty":-20.577111,"marketCap":2179751687},{"date":"2023-09-22","current":-22.590183,"twenty":-48.595885,"median":-37.578261,"eighty":-20.58462,"marketCap":2103236431},{"date":"2023-09-28","current":-22.048981,"twenty":-48.583225,"median":-37.547623,"eighty":-20.587293,"marketCap":2052848336},{"date":"2023-10-05","current":-21.978825,"twenty":-48.576545,"median":-37.531928,"eighty":-20.595005,"marketCap":2046316545},{"date":"2023-10-11","current":-21.497757,"twenty":-48.562801,"median":-37.500901,"eighty":-20.605423,"marketCap":2001527127},{"date":"2023-10-20","current":-20.345196,"twenty":-48.534663,"median":-37.448341,"eighty":-20.589221,"marketCap":1894219146},{"date":"2023-10-27","current":-19.894194,"twenty":-48.514606,"median":-37.410785,"eighty":-20.580532,"marketCap":1852229066},{"date":"2023-11-03","current":-20.485508,"twenty":-48.433814,"median":-37.299311,"eighty":-20.506205,"marketCap":1907282726},{"date":"2023-11-10","current":-20.746087,"twenty":-48.370598,"median":-37.219715,"eighty":-20.506987,"marketCap":1931543661},{"date":"2023-11-17","current":-21.217133,"twenty":-48.32991,"median":-37.120374,"eighty":-20.524091,"marketCap":1975399966},{"date":"2023-11-24","current":-21.858558,"twenty":-48.320008,"median":-37.057747,"eighty":-20.549746,"marketCap":2035119191},{"date":"2023-11-30","current":-22.048981,"twenty":-48.252059,"median":-36.968279,"eighty":-20.57027,"marketCap":2052848336},{"date":"2023-12-07","current":-26.625426,"twenty":-48.121131,"median":-36.925787,"eighty":-20.578821,"marketCap":2015198621},{"date":"2023-12-15","current":-28.276615,"twenty":-48.00719,"median":-36.911135,"eighty":-20.582242,"marketCap":2140172179},{"date":"2024-01-05","current":-26.103359,"twenty":-47.918569,"median":-36.904212,"eighty":-20.585288,"marketCap":1975684923},{"date":"2024-01-12","current":-31.117632,"twenty":-47.865829,"median":-36.842529,"eighty":-20.591149,"marketCap":2355200212},{"date":"2024-01-19","current":-31.627558,"twenty":-47.844972,"median":-36.829603,"eighty":-20.601178,"marketCap":2393794988},{"date":"2024-01-26","current":-29.053645,"twenty":-47.78321,"median":-36.766338,"eighty":-20.619869,"marketCap":2198983265},{"date":"2024-02-02","current":-29.32075,"twenty":-47.731847,"median":-36.504107,"eighty":-20.628421,"marketCap":2219199576},{"date":"2024-02-09","current":-29.393596,"twenty":-47.672575,"median":-36.388531,"eighty":-20.635263,"marketCap":2224713115},{"date":"2024-02-16","current":-29.733547,"twenty":-47.618326,"median":-36.095963,"eighty":-20.635379,"marketCap":2250442965},{"date":"2024-02-23","current":-28.10664,"twenty":-47.602066,"median":-35.89466,"eighty":-20.635842,"marketCap":2127307254},{"date":"2024-03-01","current":-29.332891,"twenty":-47.570415,"median":-35.678665,"eighty":-20.651153,"marketCap":2220118499},{"date":"2024-03-08","current":-29.55143,"twenty":-47.518149,"median":-35.35785,"eighty":-20.660918,"marketCap":2236659117},{"date":"2024-03-15","current":-26.009561,"twenty":-47.49129,"median":-35.24315,"eighty":-20.664708,"marketCap":2126463652},{"date":"2024-03-22","current":-25.786705,"twenty":-47.380514,"median":-34.925503,"eighty":-20.66947,"marketCap":2108243640},{"date":"2024-03-28","current":-24.935846,"twenty":-47.342533,"median":-34.589879,"eighty":-20.66947,"marketCap":2038679948},{"date":"2024-04-05","current":-25.071983,"twenty":-47.312176,"median":-34.414946,"eighty":-20.689994,"marketCap":2049810139},{"date":"2024-04-12","current":-25.888808,"twenty":-47.269427,"median":-33.423363,"eighty":-20.697474,"marketCap":2116591283},{"date":"2024-04-19","current":-23.631195,"twenty":-47.158961,"median":-33.184171,"eighty":-20.697474,"marketCap":1932015619},{"date":"2024-04-26","current":-22.916473,"twenty":-46.951231,"median":-33.003753,"eighty":-20.698257,"marketCap":1873582118},{"date":"2024-05-03","current":-23.897861,"twenty":-46.656905,"median":-32.649248,"eighty":-20.698257,"marketCap":1953817432},{"date":"2024-05-10","current":-23.114516,"twenty":-46.598159,"median":-32.247909,"eighty":-20.698257,"marketCap":1889773514},{"date":"2024-05-17","current":-24.517522,"twenty":-46.43348,"median":-31.759443,"eighty":-20.698257,"marketCap":2004479038},{"date":"2024-05-24","current":-22.904066,"twenty":-46.181838,"median":-31.451512,"eighty":-20.698257,"marketCap":1872567685},{"date":"2024-05-31","current":-20.986625,"twenty":-46.068748,"median":-31.128449,"eighty":-20.698257,"marketCap":1715803469},{"date":"2024-06-07","current":-20.224161,"twenty":-45.830813,"median":-30.643949,"eighty":-20.66395,"marketCap":1892880316},{"date":"2024-06-14","current":-21.429439,"twenty":-45.725202,"median":-30.31849,"eighty":-20.645029,"marketCap":2005688335},{"date":"2024-06-21","current":-21.357939,"twenty":-45.671397,"median":-29.967092,"eighty":-20.641966,"marketCap":1998996334},{"date":"2024-06-28","current":-23.247571,"twenty":-45.51108,"median":-29.932669,"eighty":-20.635726,"marketCap":2175856364},{"date":"2024-07-05","current":-22.542789,"twenty":-45.42729,"median":-29.794252,"eighty":-20.635726,"marketCap":2109892353},{"date":"2024-07-12","current":-21.439653,"twenty":-45.27192,"median":-29.668005,"eighty":-20.635726,"marketCap":2006644335},{"date":"2024-07-15","current":-21.807365,"twenty":-45.165128,"median":-29.6527,"eighty":-20.635726,"marketCap":2041060341},{"date":"2024-08-02","current":-20.438659,"twenty":-44.67116,"median":-29.473821,"eighty":-20.619869,"marketCap":1912956320},{"date":"2024-08-09","current":-18.937169,"twenty":-44.592228,"median":-29.326821,"eighty":-20.554877,"marketCap":1772424296},{"date":"2024-08-16","current":-19.846234,"twenty":-44.342086,"median":-29.065787,"eighty":-20.488395,"marketCap":1857508310},{"date":"2024-08-23","current":-19.366166,"twenty":-44.293477,"median":-28.968658,"eighty":-20.439367,"marketCap":1812576303},{"date":"2024-08-30","current":-20.193518,"twenty":-44.126836,"median":-28.878841,"eighty":-20.396729,"marketCap":1890012316},{"date":"2024-09-06","current":-20.851386,"twenty":-44.070828,"median":-28.815003,"eighty":-20.350301,"marketCap":1731811836},{"date":"2024-09-13","current":-19.495653,"twenty":-43.902513,"median":-28.750118,"eighty":-20.261779,"marketCap":1619211496},{"date":"2024-09-20","current":-20.358392,"twenty":-43.724824,"median":-28.493474,"eighty":-20.244564,"marketCap":1690866258},{"date":"2024-09-27","current":-20.324779,"twenty":-43.52784,"median":-28.425739,"eighty":-20.226358,"marketCap":1688074514},{"date":"2024-10-04","current":-19.753355,"twenty":-43.367535,"median":-28.373476,"eighty":-20.209123,"marketCap":1640614867},{"date":"2024-10-11","current":-20.30237,"twenty":-43.311657,"median":-28.264591,"eighty":-20.195561,"marketCap":1686213351},{"date":"2024-10-18","current":-21.030656,"twenty":-43.248031,"median":-28.136018,"eighty":-20.195561,"marketCap":1746701137},{"date":"2024-10-25","current":-20.078282,"twenty":-43.248031,"median":-28.049113,"eighty":-20.145499,"marketCap":1667601725},{"date":"2024-10-31","current":-20.649706,"twenty":-43.248031,"median":-27.765641,"eighty":-20.132647,"marketCap":1715061372},{"date":"2024-11-08","current":-22.688907,"twenty":-43.252213,"median":-27.636067,"eighty":-20.132233,"marketCap":1884427173},{"date":"2024-11-15","current":-21.960621,"twenty":-43.252213,"median":-27.448241,"eighty":-20.132233,"marketCap":1823939387},{"date":"2024-11-22","current":-22.229527,"twenty":-43.231304,"median":-27.106738,"eighty":-20.132233,"marketCap":1846273338},{"date":"2024-11-29","current":-25.707412,"twenty":-43.145724,"median":-26.876224,"eighty":-20.132233,"marketCap":1914893729},{"date":"2024-12-06","current":-25.40483,"twenty":-43.145724,"median":-26.625426,"eighty":-20.132233,"marketCap":1892354961},{"date":"2024-12-13","current":-24.521289,"twenty":-43.145724,"median":-26.466422,"eighty":-20.132233,"marketCap":1826541758},{"date":"2024-12-20","current":-22.572657,"twenty":-43.145724,"median":-26.327469,"eighty":-20.132233,"marketCap":1681392092},{"date":"2024-12-27","current":-22.173248,"twenty":-43.145724,"median":-26.203648,"eighty":-20.132233,"marketCap":1651640919},{"date":"2025-01-03","current":-21.785943,"twenty":-43.145724,"median":-26.12294,"eighty":-20.132233,"marketCap":1622791296},{"date":"2025-01-10","current":-21.434947,"twenty":-43.151859,"median":-25.994723,"eighty":-20.130744,"marketCap":1596646325},{"date":"2025-01-17","current":-22.584761,"twenty":-43.151859,"median":-25.832017,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-24","current":-22.584761,"twenty":-43.151859,"median":-25.722549,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-31","current":-22.330591,"twenty":-43.151859,"median":-25.688138,"eighty":-20.130744,"marketCap":1663361078},{"date":"2025-02-07","current":-23.032583,"twenty":-43.151859,"median":-25.544418,"eighty":-20.130744,"marketCap":1715651020},{"date":"2025-02-14","current":-23.601438,"twenty":-43.151859,"median":-25.410136,"eighty":-20.130744,"marketCap":1758023904},{"date":"2025-02-21","current":-22.149042,"twenty":-43.151859,"median":-25.353801,"eighty":-20.130744,"marketCap":1649837817},{"date":"2025-02-28","current":-21.229191,"twenty":-43.151859,"median":-25.248903,"eighty":-20.130744,"marketCap":1581319962},{"date":"2025-03-07","current":-20.902402,"twenty":-43.157994,"median":-25.114351,"eighty":-20.129255,"marketCap":1556978093},{"date":"2025-03-14","current":-25.841364,"twenty":-43.157994,"median":-25.015259,"eighty":-20.118618,"marketCap":1407320673},{"date":"2025-03-21","current":-31.526661,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1716941957},{"date":"2025-03-28","current":-31.810986,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1732426315},{"date":"2025-04-04","current":-28.415807,"twenty":-43.157994,"median":-25.140052,"eighty":-20.118618,"marketCap":1547524873},{"date":"2025-04-11","current":-25.672904,"twenty":-43.151859,"median":-25.115856,"eighty":-20.120859,"marketCap":1398146368},{"date":"2025-04-17","current":-25.238054,"twenty":-43.151859,"median":-25.115856,"eighty":-20.120859,"marketCap":1374464410},{"date":"2025-04-25","current":-26.22483,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1428204238},{"date":"2025-05-02","current":-26.007405,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1416363259},{"date":"2025-05-09","current":-26.208105,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1427293394},{"date":"2025-05-16","current":-28.064582,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1528397138},{"date":"2025-05-23","current":-26.826931,"twenty":-43.110374,"median":-25.054079,"eighty":-20.118618,"marketCap":1460994642},{"date":"2025-05-30","current":-40.212905,"twenty":-43.110374,"median":-25.054079,"eighty":-20.118618,"marketCap":1483896395},{"date":"2025-06-06","current":-38.417271,"twenty":-42.89345,"median":-25.054079,"eighty":-20.118618,"marketCap":1417635735},{"date":"2025-06-11","current":-39.541314,"twenty":-42.85482,"median":-25.054079,"eighty":-20.118618,"marketCap":1459114024}],"updateTime":1749746439598}}}